Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Financing Activities (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Cash from Financing Activities for 11 consecutive years, with $9.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 579787.3% to $9.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $24.8 million, a 24527.9% increase, with the full-year FY2024 number at $15.0 million, up 1256.54% from a year prior.
  • Cash from Financing Activities was $9.9 million for Q3 2025 at Marker Therapeutics, up from $100.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $52.7 million in Q1 2021 to a low of -$100743.0 in Q2 2021.
  • A 5-year average of $5.2 million and a median of $49096.0 in 2024 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 579787.3% in 2025; the steepest drop was 99.78% in 2025.
  • Marker Therapeutics' Cash from Financing Activities stood at -$100743.0 in 2021, then soared by 237.41% to $138427.0 in 2022, then plummeted by 96.29% to $5135.0 in 2023, then soared by 289985.9% to $14.9 million in 2024, then plummeted by 33.78% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Cash from Financing Activities are $9.9 million (Q3 2025), $100.0 (Q2 2025), and $505.0 (Q1 2025).